Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.17608 http://scihub22266oqcxt.onion/10.1111/bjh.17608 34196388!8444771!34196388     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Haematol 2021 ; 195 (2): 186-193 Nephropedia Template TP {{tp|p=34196388|t=2021. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma |pdf=|usr=}}{{34196388}} gab.com Text Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=34196388 #FOAvip Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA COVID19 (BNT162b2) vaccine provides effective protection against COVID19 for the general population, yet its effect in MM patients may be compromised due to disease and therapy-related factors and was not yet evaluated. This single-centre prospective study included MM patients tested for serological response 14-21 days post second vaccine. Vaccinated healthy volunteers served as controls. In all, 171 MM patients, median age 70 (38-94) were included; 159 active MM and 12 smouldering myeloma (SMM). Seropositive response rate (median titer) was 76% (91 U/ml) in active MM patients vs 98% (992 U/ml) in the 64 controls (P < 0.0001), and 100% (822 U/ml) in SMM patients. Multivariate analysis revealed older age (P = 0.009), exposure to >/=4 novel anti-myeloma drugs (P = 0.02) and hypogammaglobulinaemia (P = 0.002) were associated with lower response rates. None of the novel agents significantly decreased response rate, whereas daratumumab trended towards reduced response (P = 0.08). Adverse events occurred in 53% and 55% of the MM patients and controls, respectively, all transient grade 1-2. In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type. Older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates. Twit Text FOAVip Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=34196388 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34196388 #FOAvip English Wikipedia <ref>{{Cite pmid|34196388}}</ref> Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma #MMPMID34196388 Avivi I; Balaban R; Shragai T; Sheffer G; Morales M; Aharon A; Lowenton-Spier N; Trestman S; Perry C; Benyamini N; Mittelman M; Tabib Y; Bar Lev T; Zavaro M; Herishanu Y; Luttwak E; Cohen YC Br J Haematol 2021[Oct]; 195 (2): 186-193 PMID34196388show ga Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA COVID19 (BNT162b2) vaccine provides effective protection against COVID19 for the general population, yet its effect in MM patients may be compromised due to disease and therapy-related factors and was not yet evaluated. This single-centre prospective study included MM patients tested for serological response 14-21 days post second vaccine. Vaccinated healthy volunteers served as controls. In all, 171 MM patients, median age 70 (38-94) were included; 159 active MM and 12 smouldering myeloma (SMM). Seropositive response rate (median titer) was 76% (91 U/ml) in active MM patients vs 98% (992 U/ml) in the 64 controls (P < 0.0001), and 100% (822 U/ml) in SMM patients. Multivariate analysis revealed older age (P = 0.009), exposure to >/=4 novel anti-myeloma drugs (P = 0.02) and hypogammaglobulinaemia (P = 0.002) were associated with lower response rates. None of the novel agents significantly decreased response rate, whereas daratumumab trended towards reduced response (P = 0.08). Adverse events occurred in 53% and 55% of the MM patients and controls, respectively, all transient grade 1-2. In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type. Older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates. |Adult[MESH] |Agammaglobulinemia/complications[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal/adverse effects[MESH] |BNT162 Vaccine/administration & dosage/*adverse effects/immunology[MESH] |COVID-19 Vaccines/administration & dosage/*adverse effects/immunology[MESH] |COVID-19/diagnosis/epidemiology/immunology/*prevention & control[MESH] |Case-Control Studies[MESH] |Female[MESH] |Humans[MESH] |Immunity, Humoral/drug effects/*immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Myeloma/complications/diagnosis/*immunology[MESH] |Multivariate Analysis[MESH] |Predictive Value of Tests[MESH] |Prospective Studies[MESH] |Risk Factors[MESH] |SARS-CoV-2/genetics[MESH]Humoral response rate and predictors of response to BNT162b2 mRNA COVI(epmc).pdf DeepDyve Pubget Overpricing